Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome?
Drug Discov Ther
; 14(5): 259-261, 2020 Nov 04.
Article
in English
| MEDLINE | ID: covidwho-895584
ABSTRACT
Regardless of the severity of coronavirus disease 2019 (COVID-19), a high proportion of patients struggle with persistent respiratory or systemic symptoms after recovery. This is called "postCOVID syndrome", for which pulmonary fibrosis is one of the pathogenesis. Besides T-lymphocytes and macrophages, mast cells also contribute to the development of cytokine storm and thus stimulate the activity of fibroblasts. Additionally, by the exocytotic release of fibroblast-activating factors, mast cells directly facilitate the progression of pulmonary fibrosis. In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed their potency as highly effective mast cell stabilizers. Given such pharmacological properties of these commonly used drugs, they may be useful in the treatment of post-COVID-19 pulmonary fibrosis and in relieving the symptoms of post-COVID syndrome.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Pulmonary Fibrosis
/
Cell Degranulation
/
Adrenal Cortex Hormones
/
Coronavirus Infections
/
Anti-Allergic Agents
/
Betacoronavirus
/
Mast Cells
/
Anti-Bacterial Agents
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Animals
/
Humans
Language:
English
Journal:
Drug Discov Ther
Year:
2020
Document Type:
Article
Affiliation country:
Ddt.2020.03095
Similar
MEDLINE
...
LILACS
LIS